|
Further to the announcement by the Company on 25 January 2005 of the acquisition of Ebiox Limited (“Ebiox”), HCEG is pleased to announce that the first milestones agreed under the terms of the acquisition have been met in full and accordingly HCEG has allotted 250,000 new ordinary shares of 2.5p each in the capital of the Company to the vendors of Ebiox.
Application has been made for the new ordinary shares to be admitted to AIM, bringing the issued share capital of the Company to 150,604,079.
Stuart Bruck, Executive Chairman, Healthcare Enterprise Group PLC, commented:
“We are pleased that Ebiox has achieved these milestones completing the Ebiox range for instrument decontamination, in line with our expectations. Ebiox has now been proven to outperform the requirements laid down by the regulatory and clinical bodies worldwide. The annual worldwide market for high level endoscope disinfectant alone is worth $300 million.”
Enquiries:
Healthcare Enterprise Group
John Bradshaw, Group Finance Director
020 7351 7500
College Hill
Corinna Dorward
Adrian Duffield
020 7457 2020
Notes
Healthcare Enterprise Group PLC
HCEG is quoted on the UK AIM stock market with its head office in London. HCEG is a business engaged in medical product distribution, occupational health, first aid and medical consultancy markets. These businesses underpin a range of innovative medical devices, which will be introduced to the market via HCEG’s own distribution network on an international basis.
|
